Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia

Movement Disorders

Volumn 29, Issue 7, 2014, Pages 935-939

  Boesch, Sylvia ^a   Nachbauer, Wolfgang ^a   Mariotti, Caterina ^b   Sacca, Francesco ^c   Filla, Alessandro ^c   Klockgether, Thomas ^d,g   Klopstock, Thomas ^e   Schöls, Ludger ^f,g   Jacobi, Heike ^d   Büchner, Boriana ^e   vom Hagen, Jennifer Müller ^f   Nanetti, Lorenzo ^b   Manicom, Karen ^h  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^h H LUNDBECK A S   (Denmark)

Author keywords

Carbamylated erythropoietin; Erythropoietin; Frataxin; Friedreich's ataxia

Indexed keywords

CARBAMYLATED ERYTHROPOIETIN; CENTRAL NERVOUS SYSTEM AGENTS; FRATAXIN; LU AA 24493; PLACEBO; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ERYTHROPOIETIN; IRON BINDING PROTEIN;

ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRIEDREICH ATAXIA; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; MALE; MULTICENTER STUDY; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; METABOLISM; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; FRIEDREICH ATAXIA; HUMANS; IRON-BINDING PROTEINS; MALE; TREATMENT OUTCOME;

EID: 84902297511     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25836     Document Type: Article

References (37)

1. Epplen C, Epplen JT, Frank G, Miterski B, Santos EJ, Schols L. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum Genet 1997;99:834-836.
2. Pandolfo M. Friedreich's ataxia: clinical aspects and pathogenesis. Semin Neurol 1999;19:311-321.
3. Pandolfo M. Molecular basis of Friedreich ataxia. Mov Disord 2001;16:815-821.
4. Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981;104:589-620.
5. Schulz JB, Boesch S, Burk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 2009;5:222-234.
6. Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996;59:554-560.
7. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 1996;335:1169-1175.
8. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996;271:1423-1427.
9. Cossee M, Durr A, Schmitt M, et al. Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999;45:200-206.
10. Adinolfi S, Iannuzzi C, Prischi F, et al. Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS. Nat Struct Mol Biol 2009;16:390-396.
11. Yoon T, Cowan JA. Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J Am Chem Soc 2003;125:6078-6084.
12. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A 1999;96:11492-11495.
13. Bradley JL, Homayoun S, Hart PE, Schapira AH, Cooper JM. Role of oxidative damage in Friedreich's ataxia. Neurochem Res 2004;29:561-567.
14. Boesch S, Sturm B, Hering S, Goldenberg H, Poewe W, Scheiber-Mojdehkar B. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol 2007;62:521-524.
15. Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest 2005;35:711-717.
16. Sturm B, Helminger M, Steinkellner H, Heidari MM, Goldenberg H, Scheiber-Mojdehkar B. Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur J Clin Invest 2010;40:561-565.
17. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010;29:86-92.
18. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
19. Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717-1720.
20. Burk K, Malzig U, Wolf S, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 2009;24:1779-1784.
21. Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 2005;64:1261-1262.
22. Deutsch EC, Santani AB, Perlman SL, et al. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab 2010;101:238-245.
23. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008;3:e1958.
24. Marmolino D, Acquaviva F, Pinelli M, et al. PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy. Cerebellum 2009;8:98-103.
25. Soragni E, Xu C, Cooper A, Plasterer HL, Rusche JR, Gottesfeld JM. Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol Biol 2011;793:495-508.
26. Ghazizadeh M. Cisplatin may induce frataxin expression. J Nihon Med Sch 2003;70:367-371.
27. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006;2:551-558.
28. Acquaviva F, Castaldo I, Filla A, et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 2008;7:360-365.
29. Mariotti C, Fancellu R, Caldarazzo S, et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord 2012;27:446-449.
30. Sacca F, Puorro G, Antenora A, et al. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS One 2011;6:e17627.
31. Steinkellner H, Scheiber-Mojdehkar B, Goldenberg H, Sturm B. A high throughput electrochemiluminescence assay for the quantification of frataxin protein levels. Anal Chim Acta 2010;659:129-132.
32. Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF. Lateral-flow immunoassay for the frataxin protein in Friedreich's ataxia patients and carriers. Mol Genet Metab 2008;94:491-497.
33. Nachbauer W, Wanschitz J, Steinkellner H, et al. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Mov Disord 2011;26:1935-1938.
34. Sacca F, Piro R, De Michele G, et al. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Mov Disord 2011;26:739-742.
35. Nachbauer W, Hering S, Seifert M, et al. Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia-a dose-response trial. Cerebellum 2011;10:763-769.
36. Becker E, Richardson DR. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int J Biochem Cell Biol 2001;33:1-10.
37. Hori A, Mizoue T, Kasai H, et al. Body iron store as a predictor of oxidative DNA damage in healthy men and women. Cancer Sci 2010;101:517-522.